2023
Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitor
McNamara B, Harold J, Manavella D, Bellone S, Mutlu L, Hartwich T, Zipponi M, Yang-Hartwich Y, Demirkiran C, Verzosa M, Yang K, Choi J, Dong W, Buza N, Hui P, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Burton E, Inagaki H, Albers A, Zhang C, Bollag G, Schlessinger J, Santin A. Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitor. Gynecologic Oncology 2023, 172: 65-71. PMID: 36958197, PMCID: PMC10192120, DOI: 10.1016/j.ygyno.2023.03.009.Peer-Reviewed Original ResearchConceptsUterine leiomyosarcomaPDX modelsGain of functionMedian overall survivalPhase I trialOral gavage dailyVivo activityTumor growth inhibitionTumor volume differencesTumor cell proliferationOverall survivalTolerable toxicityI trialOral treatmentTreatment cohortsGavage dailyAggressive tumorsSCID miceULMS patientsPK studiesTumor samplesWestern blotCell proliferationControl vehicleLeiomyosarcoma
2022
Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma
Harold J, Bellone S, Manavella D, Mutlu L, McNamara B, Hartwich T, Zipponi M, Yang-Hartwich Y, Demirkiran C, Verzosa M, Choi J, Dong W, Buza N, Hui P, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Santin A. Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma. Gynecologic Oncology 2022, 168: 157-165. PMID: 36442427, PMCID: PMC9797429, DOI: 10.1016/j.ygyno.2022.11.014.Peer-Reviewed Original ResearchConceptsPatient-derived xenograftsUterine leiomyosarcomaVivo activityVehicle control treatmentMedian overall survivalTumor volume differencesOral scheduleWestern blot analysisOverall survivalOral gavageAggressive malignancyPDX modelsClinical trialsSCID miceTumor measurementsULMS patientsSignificant growth inhibitionNovel ATR inhibitorTumor samplesSignificant toxicityWestern blotKinase inhibitorsATRX mutationsGene mutationsControl vehicle
2021
Endometrial Sampling for Preoperative Diagnosis of Uterine Leiomyosarcoma
Kho RM, Desai VB, Schwartz PE, Wright JD, Gross CP, Hutchison LM, Boscoe FP, Lin H, Xu X. Endometrial Sampling for Preoperative Diagnosis of Uterine Leiomyosarcoma. Journal Of Minimally Invasive Gynecology 2021, 29: 119-127. PMID: 34265441, PMCID: PMC8752465, DOI: 10.1016/j.jmig.2021.07.004.Peer-Reviewed Original ResearchMeSH KeywordsEndometrial NeoplasmsEndometriumFemaleHumansHysterectomyLeiomyosarcomaRetrospective StudiesUterine NeoplasmsConceptsEndometrial samplingUterine leiomyosarcomaPreoperative diagnosisPreoperative detectionNew York State Cancer RegistryNew York Statewide PlanningPreoperative endometrial samplingSuboptimal surgical managementUse of hysteroscopyOutcomes of patientsRetrospective cohort studyState Cancer RegistryMultivariable regression analysisResearch Cooperative SystemAmbulatory surgery centersSample eligibility criteriaRace/ethnicityIndex surgeryCohort studyLocalized stageSupracervical hysterectomyCancer RegistryOutpatient encountersSurgical managementTumor sizeProton radiotherapy for recurrent or metastatic sarcoma with palliative quad shot
Lee A, Kang J, Bernstein H, Marqueen K, Neal B, Kelly C, Dickson M, Tsai C, Tap W, Singer S, Alektiar K, Lee N. Proton radiotherapy for recurrent or metastatic sarcoma with palliative quad shot. Cancer Medicine 2021, 10: 4221-4227. PMID: 34085781, PMCID: PMC8267151, DOI: 10.1002/cam4.3646.Peer-Reviewed Original ResearchConceptsLocal progression-free survivalMetastatic sarcomaSystemic therapyQUAD ShotOverall survivalUnivariate analysisPalliative responseMedian local progression-free survivalGrade 3 acute toxicityFurther systemic therapyProgression-free survivalConcurrent systemic therapyProton therapyCommon histologyMedian followProton RTTreatment optionsRadiation therapyPatientsLocal controlSarcomaTherapyRegimenProton radiotherapyAcute toxicityIntegrated mutational landscape analysis of uterine leiomyosarcomas
Choi J, Manzano A, Dong W, Bellone S, Bonazzoli E, Zammataro L, Yao X, Deshpande A, Zaidi S, Guglielmi A, Gnutti B, Nagarkatti N, Tymon-Rosario JR, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Jeong K, Zhao S, Buza N, Hui P, Ravaggi A, Bignotti E, Romani C, Todeschini P, Zanotti L, Odicino F, Pecorelli S, Ardighieri L, Bilguvar K, Quick CM, Silasi DA, Huang GS, Andikyan V, Clark M, Ratner E, Azodi M, Imielinski M, Schwartz PE, Alexandrov LB, Lifton RP, Schlessinger J, Santin AD. Integrated mutational landscape analysis of uterine leiomyosarcomas. Proceedings Of The National Academy Of Sciences Of The United States Of America 2021, 118: e2025182118. PMID: 33876771, PMCID: PMC8053980, DOI: 10.1073/pnas.2025182118.Peer-Reviewed Original ResearchConceptsHomologous recombination DNA repair deficiencySequencing dataWhole-genome sequencing dataRNA sequencing dataTCGA samplesCopy number variation analysisATRX/DAXXCopy number lossNumber variation analysisDNA repair deficiencyWhole-exome sequencing dataRecurrent somatic mutationsCopy number gainsCancer Genome AtlasPatient-derived xenograftsTumor suppressorAkt geneGenetic landscapeHRD signaturesPTEN geneGenesMost fusionsC-MycMutational signaturesC-myc/
2019
Prevalence, characteristics, and risk factors of occult uterine cancer in presumed benign hysterectomy
Desai VB, Wright JD, Gross CP, Lin H, Boscoe FP, Hutchison LM, Schwartz PE, Xu X. Prevalence, characteristics, and risk factors of occult uterine cancer in presumed benign hysterectomy. American Journal Of Obstetrics And Gynecology 2019, 221: 39.e1-39.e14. PMID: 30853364, PMCID: PMC7006101, DOI: 10.1016/j.ajog.2019.02.051.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAsianBlack or African AmericanComorbidityEndometrial NeoplasmsEndometriosisEthnicityFemaleHispanic or LatinoHumansHysterectomyIncidental FindingsLeiomyomaLeiomyosarcomaMenstruation DisturbancesMetrorrhagiaMiddle AgedObesityPrevalenceRisk AssessmentRisk FactorsSarcomaUnited StatesUterine NeoplasmsUterine ProlapseWhite PeopleYoung AdultConceptsOccult uterine cancerUterine cancerBenign indicationsRisk factorsUterine sarcomaBenign hysterectomyEndometrial carcinomaPredictive valueResearch Cooperative System databaseState cancer registry dataNew York Statewide PlanningHigh negative predictive valueLow positive predictive valueAssociated risk factorsCorpus uteri cancerLarge population-based sampleCancer registry dataPopulation-based sampleAmbulatory surgery centersNegative predictive valuePositive predictive valueRisk prediction modelRace/ethnicityPostmenopausal bleedingPatient characteristics
2018
Resection of retroperitoneal sarcoma en‐bloc with inferior vena cava: 20 year outcomes of a single institution
Blair AB, Reames BN, Singh J, Gani F, Overton HN, Beaulieu RJ, Lum YW, Black JH, Johnston FM, Ahuja N. Resection of retroperitoneal sarcoma en‐bloc with inferior vena cava: 20 year outcomes of a single institution. Journal Of Surgical Oncology 2018, 118: 127-137. PMID: 29878363, PMCID: PMC6220674, DOI: 10.1002/jso.25096.Peer-Reviewed Original Research
2017
Leiomyosarcoma of the infratemporal fossa with perineurial spread along the right mandibular nerve: a case report
Barbiero FJ, Huttner AJ, Judson BL, Baehring JM. Leiomyosarcoma of the infratemporal fossa with perineurial spread along the right mandibular nerve: a case report. CNS Oncology 2017, 06: 281-285. PMID: 28990793, PMCID: PMC6004886, DOI: 10.2217/cns-2017-0004.Peer-Reviewed Original ResearchConceptsMandibular nerveRight mandibular nerveRight cavernous sinusSmooth muscle differentiationNerve biopsyCase reportMass lesionNeck cancerCavernous sinusMalignant tumorsGI tractInfratemporal fossaMedical literatureLeiomyosarcomaSkin appendagesSimilar casesNerveTumorsMuscle differentiationPeculiar patternDiplopiaHeadacheBiopsyPatientsMyometrium
2014
Recurrent chromosomal aberrations in intravenous leiomyomatosis of the uterus: high-resolution array comparative genomic hybridization study
Buza N, Xu F, Wu W, Carr RJ, Li P, Hui P. Recurrent chromosomal aberrations in intravenous leiomyomatosis of the uterus: high-resolution array comparative genomic hybridization study. Human Pathology 2014, 45: 1885-1892. PMID: 25033729, DOI: 10.1016/j.humpath.2014.05.010.Peer-Reviewed Original ResearchConceptsOligonucleotide array comparative genomic hybridizationArray comparative genomic hybridizationComparative genomic hybridizationGenome-wide investigationGenomic hybridizationChromosome 22qCopy number lossGene mappingChromosomal aberrationsComparative genomic hybridization studySuccinate dehydrogenase subunit BGenetic instabilityRecurrent chromosomal aberrationsRegions of lossSequencing analysisChromosome 12qNumber lossNumber variantsSubunit BChromosomal alterationsHybridization studies
2012
Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors
Macaulay V, Middleton M, Protheroe A, Tolcher A, Dieras V, Sessa C, Bahleda R, Blay J, LoRusso P, Mery-Mignard D, Soria J. Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors. Annals Of Oncology 2012, 24: 784-791. PMID: 23104723, PMCID: PMC3574548, DOI: 10.1093/annonc/mds511.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsDeoxycytidineDiarrheaDocetaxelDoxorubicinErlotinib HydrochlorideFemaleGemcitabineHumansLeiomyosarcomaMaleMelanomaMiddle AgedQuinazolinesReceptor, IGF Type 1Skin NeoplasmsSoft Tissue NeoplasmsTaxoidsTreatment OutcomeConceptsAdvanced solid tumorsInsulin-like growth factor receptorType 1 insulin-like growth factor receptorGrowth factor receptorIGF-IISolid tumorsDisease controlCommon adverse eventsFactor receptorIGF-1R antibodyDurable disease controlCohort C2Adverse eventsPartial responseCohort BDocetaxel administrationSteroid premedicationControl ratePK interactionsGrade 3IGF-BP3Blood samplesCohort C1PatientsAVE1642
2007
Metastatic Uterine Leiomyosarcoma Regression Using an Aromatase Inhibitor
Hardman MP, Roman JJ, Burnett AF, Santin AD. Metastatic Uterine Leiomyosarcoma Regression Using an Aromatase Inhibitor. Obstetrics And Gynecology 2007, 110: 518-520. PMID: 17666649, DOI: 10.1097/01.aog.0000267533.56546.c2.Peer-Reviewed Original ResearchConceptsUterine leiomyosarcomaAromatase inhibitorsTotal abdominal hysterectomyUterine leiomyosarcoma metastaticEstrogen receptor positivityPrimary uterine leiomyosarcomaMetastatic tumor nodulesAdjuvant platinumAnastrozole dailyLeiomyosarcoma metastaticAbdominal hysterectomyObjective responseReceptor positivityTumor depositsChemotherapeutic optionsDoxorubicin chemotherapySerial imagingTumor regressionTumor nodulesLeiomyosarcomaLungInhibitorsHysterectomyNulligravidaMetastaticManagement of primary liver sarcomas
Weitz J, Klimstra D, Cymes K, Jarnagin W, D'Angelica M, La Quaglia M, Fong Y, Brennan M, Blumgart L, DeMatteo R. Management of primary liver sarcomas. Cancer 2007, 109: 1391-1396. PMID: 17315167, DOI: 10.1002/cncr.22530.Peer-Reviewed Original ResearchConceptsDisease-specific survivalPrimary hepatic sarcomaR0 resectionHepatic sarcomaPrimary carcinosarcomaEffective systemic therapyLow-grade sarcomaOutcomes of patientsHigh-grade sarcomaLong-term outcomesActuarial survivalTumor characteristicsTumor histologyTumor recurrenceEmbryonal sarcomaRare entitySystemic therapyPrognostic factorsTumor resectionEpithelioid hemangioendotheliomaPrimary sarcomaDisease-freePatient demographicsStable lesionsSarcoma
2003
Eosinophilia and uterine leiomyosarcoma.
Pal L, Parkash V, Chambers JT. Eosinophilia and uterine leiomyosarcoma. Obstetrics And Gynecology 2003, 101: 1130-2. PMID: 12738126, DOI: 10.1016/s0029-7844(02)02338-4.Peer-Reviewed Original ResearchConceptsUterine leiomyosarcomaTissue eosinophiliaOffice-based endometrial biopsyPelvic lymph node dissectionTumor-associated tissue eosinophiliaLow-grade uterine leiomyosarcomaEvidence of leukocytosisMarked eosinophilic infiltratePreoperative laboratory assessmentLymph node dissectionTotal abdominal hysterectomyGynecologic oncology serviceTertiary care hospitalImmediate postoperative periodSpectrum of neoplasmsNormalization of valuesAbsolute eosinophiliaSystemic eosinophiliaSystemic leukocytosisAbdominal hysterectomyBlood eosinophiliaExploratory laparotomyNode dissectionPostmenopausal bleedingPostmenopausal womenGastrointestinal Leiomyosarcoma in 14 Dogs
Cohen M, Post G, Wright J. Gastrointestinal Leiomyosarcoma in 14 Dogs. Journal Of Veterinary Internal Medicine 2003, 17: 107-110. PMID: 12564735, DOI: 10.1111/j.1939-1676.2003.tb01331.x.Peer-Reviewed Original ResearchConceptsImmediate postoperative periodIntestinal leiomyosarcomaPostoperative periodTime of surgeryCommon clinical signsClinical characteristic featuresLong-term survivalMedian survivalRetrospective reviewSurgical excisionGastrointestinal leiomyosarcomaLonger survivalClinical signsMean survivalSurvival rateLeiomyosarcomaDogsSurvivalSurgeryMonthsPolyuriaHypoglycemiaPolydipsiaAnemiaMetastasis
1969
Sarcoma of the pulmonary trunk associated with hemorrhagic tendency: A case report and review of the literature
Wackers F, Van Der Schoot J, Hampe J. Sarcoma of the pulmonary trunk associated with hemorrhagic tendency: A case report and review of the literature. Cancer 1969, 23: 339-351. PMID: 5764975, DOI: 10.1002/1097-0142(196902)23:2<339::aid-cncr2820230210>3.0.co;2-s.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply